[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Heo HS, Kim JH, Lee YJ, Kim SH, Cho YS, Kim CG: Microarray profiling of genes differentially expressed during erythroid differentiation of murine erythroleukemia cells. Mol Cells; 2005 Aug 31;20(1):57-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray profiling of genes differentially expressed during erythroid differentiation of murine erythroleukemia cells.
  • Murine erythroleukemia (MEL) cells are widely used to study erythroid differentiation thanks to their ability to terminally differentiate in vitro in response to chemical induction.
  • At the molecular level, not much is known of their terminal differentiation apart from activation of adult-type globin gene expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258242.001).
  • [ISSN] 1016-8478
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Acetamides; 0 / Genetic Markers; LA133J59VU / hexamethylene bisacetamide
  •  go-up   go-down


2. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F: Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia; 2009 Dec;23(12):2275-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
  • Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Myelodysplastic Syndromes / complications. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):34-40 [1615923.001]
  • [Cites] Blood. 1992 Oct 15;80(8):1869-79 [1391951.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2873-82 [1450412.001]
  • [Cites] Blood Rev. 1992 Dec;6(4):204-14 [1486289.001]
  • [Cites] Am J Hematol. 1995 May;49(1):29-38 [7741135.001]
  • [Cites] Br J Haematol. 1995 Aug;90(4):868-75 [7669665.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):42-7 [9499256.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):15-9 [9595039.001]
  • [Cites] Leuk Lymphoma. 1998 Jul;30(3-4):395-401 [9713970.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Am J Clin Pathol. 1998 Nov;110(5):590-8 [9802343.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):99-107 [10512167.001]
  • [Cites] Blood. 1958 Feb;13(2):192-4 [13510296.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):113-22 [16337853.001]
  • [Cites] Blood. 1986 Nov;68(5):1167-74 [2945604.001]
  • [Cites] Acta Haematol. 1987;77(4):193-7 [3115028.001]
  • [Cites] Semin Oncol. 1987 Dec;14(4):425-34 [3321447.001]
  • [Cites] Leukemia. 1989 Apr;3(4):305-9 [2927179.001]
  • [Cites] Blood. 2006 Feb 1;107(3):880-4 [16123215.001]
  • [Cites] Am J Hematol. 2006 Jul;81(7):484-91 [16755568.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2314-21 [17158236.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):17-22 [16856158.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):346-55 [18692685.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Fall;11(3):348-59 [2675661.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):330-1 [10656753.001]
  • [Cites] Clin Lab Med. 2000 Mar;20(1):119-37 [10702900.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):5-13 [10936857.001]
  • [Cites] Intern Med. 2000 Oct;39(10):761-2 [11030195.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Pathol. 2001 Mar;54(3):205-9 [11253132.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):65-75 [11355924.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):737-45 [11380465.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):667-8 [11392312.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):451-5 [11398875.001]
  • [Cites] Haematologica. 2002 Feb;87(2):148-53 [11836165.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3135-40 [12384410.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):406-12 [12619165.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):939-43 [12648062.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1362-5 [14521454.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1276-86 [14970186.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 2):4833-7 [6945906.001]
  • [Cites] Blood. 1983 Apr;61(4):645-51 [6572533.001]
  • [Cites] Br J Haematol. 1990 Jul;75(3):346-54 [2386768.001]
  • (PMID = 19741728.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / U54 CA096300
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS636030; NLM/ PMC4217206
  •  go-up   go-down


3. Olave IA, Doneanu C, Fang X, Stamatoyannopoulos G, Li Q: Purification and identification of proteins that bind to the hereditary persistence of fetal hemoglobin -198 mutation in the gamma-globin gene promoter. J Biol Chem; 2007 Jan 12;282(2):853-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the gamma-globin gene is silenced in adult humans.
  • However, certain point mutations in the gamma-globin gene promoter are capable of maintaining expression of this gene during adult erythropoiesis, a condition called non-deletion hereditary persistence of fetal hemoglobin (HPFH).
  • In this study, we used nuclear extracts from murine erythroleukemia cells to purify a protein complex that binds the HPFH -198 gamma-globin gene promoter.
  • The potential role of these proteins in the reactivation and/or maintenance of gamma-globin gene expression in the adult transcriptional environment is discussed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1993 Sep 25;268(27):20482-9 [8376403.001]
  • [Cites] Nucleic Acids Res. 1989 Dec 25;17(24):10231-41 [2481268.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2593-603 [8139561.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20682-90 [8051169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5655-9 [7539923.001]
  • [Cites] Nature. 1996 Feb 1;379(6564):466-9 [8559255.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13371-6 [8917598.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5833-7 [9038199.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2130-42 [9528785.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6723-9 [9822615.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5492-9 [9710633.001]
  • [Cites] Ann N Y Acad Sci. 1998 Jun 30;850:38-44 [9668525.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):751-9 [9885563.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:83-103 [10384273.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):689-96 [10440698.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24250-6 [10446200.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7452-9 [15613485.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):88-91 [10615135.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):265-73 [10721720.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):338-42 [10888886.001]
  • [Cites] Genes Cells. 2000 Aug;5(8):677-88 [10947852.001]
  • [Cites] Nucleic Acids Res. 1990 Oct 11;18(19):5685-93 [1699206.001]
  • [Cites] Blood. 1991 Oct 1;78(7):1853-63 [1912570.001]
  • [Cites] Nature. 1992 Aug 6;358(6386):499-502 [1379347.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):166-79 [11082287.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6569-81 [11101529.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):147-78 [11237318.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):157-64 [11226166.001]
  • [Cites] Mol Cell Biol. 2001 May;21(9):3083-95 [11287613.001]
  • [Cites] EMBO J. 2001 Aug 15;20(16):4337-40 [11500360.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):779-88 [11847125.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5361-79 [12154399.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):61-5 [12496760.001]
  • [Cites] Genome Biol. 2003;4(2):206 [12620113.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2834-43 [12665582.001]
  • [Cites] Nucleic Acids Res. 2003 May 1;31(9):2305-12 [12711675.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4056-65 [12773551.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3511-7 [12789259.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jan;11(1):73-80 [14718926.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27915-27 [15087453.001]
  • [Cites] J Biol Chem. 1989 May 25;264(15):8913-21 [2566609.001]
  • [Cites] Nature. 1989 Jun 8;339(6224):446-51 [2725678.001]
  • [Cites] EMBO J. 1994 Jan 15;13(2):471-83 [8313892.001]
  • (PMID = 17114178.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK045365; United States / NIDDK NIH HHS / DK / R37 DK045365-07S1; United States / NIDDK NIH HHS / DK / DK61805; United States / NIDDK NIH HHS / DK / DK045365-07S1; United States / NIDDK NIH HHS / DK / R37 DK045365; United States / NIDDK NIH HHS / DK / R01 DK061805; United States / NIDDK NIH HHS / DK / DK045365-06S1; United States / NHLBI NIH HHS / HL / HL73439; United States / NIDDK NIH HHS / DK / R01 DK045365-06S1; United States / NHLBI NIH HHS / HL / R01 HL073439; United States / NIDDK NIH HHS / DK / R01 DK045365; United States / NIDDK NIH HHS / DK / DK45365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Matrix-Associated Proteins; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; 0 / Transcription Factors, TFII; 9004-22-2 / Globins; 9034-63-3 / Fetal Hemoglobin; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 3.6.4.12 / transcription factor TFIIF
  • [Other-IDs] NLM/ NIHMS172023; NLM/ PMC2819221
  •  go-up   go-down


Advertisement
4. Niu Y, Chen SC, Jiang B, Li DG, Ge CW, Li RS: [Erythroleukemia - a subtype of myelodysplastic syndrome?]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):219-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Erythroleukemia - a subtype of myelodysplastic syndrome?].
  • In order to study whether erythroleukemia was really a subtype of acute leukemia, the clinical laboratory characteristics and development of disease in 21 cases of erythroleukemia were analyzed.


5. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CE: Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol; 2010 Aug;23(8):1113-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the current World Health Organization classification criteria, we retrospectively reviewed cases of acute myeloid leukemia or myelodysplastic syndrome in which erythroid precursors were >or=50% of the bone marrow nucleated cell population and the diagnosis of erythroleukemia was considered using older classification schemes.
  • We collected 90 cases and separated them into four diagnostic groups: acute erythroid leukemia, erythroleukemia or erythroid/myeloid type (n=20); acute myeloid leukemia with myelodysplasia-related changes (n=22); therapy-related acute myeloid leukemia (n=32); and refractory anemia with excess blasts and preceding or concurrent history of erythropoietin therapy for anemia (n=16).
  • A majority of the cases reported previously as erythroleukemia are now classified as other entities.
  • In addition, our data suggest that the current definition of acute erythroid leukemia, erythroleukemia type remains heterogeneous.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anemia, Refractory / pathology. Bone Marrow Cells / pathology. Bone Marrow Transplantation. Child. Chromosome Aberrations. Erythroblasts / pathology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Texas / epidemiology. World Health Organization. Young Adult

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473273.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Manwani D, Galdass M, Bieker JJ: Altered regulation of beta-like globin genes by a redesigned erythroid transcription factor. Exp Hematol; 2007 Jan;35(1):39-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: As would be predicted, when introduced transiently into cells these transcription factors were effective in repressing the adult beta-globin promoter CACCC element, which is the natural target for EKLF.
  • In murine erythroleukemia cells repression of the adult beta-globin gene was accompanied by a reactivation of the endogenous embryonic betaH1-globin gene.
  • CONCLUSION: Our studies support a competition model for beta-globin gene expression and underscore the importance of EKLF in the embryonic/fetal-to-adult globin switch.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2485-90 [15489291.001]
  • [Cites] Gene Ther. 2003 Mar;10(6):513-22 [12621455.001]
  • [Cites] Blood. 1988 Sep;72(3):1007-14 [2458145.001]
  • [Cites] Cell. 1988 Oct 7;55(1):17-26 [3167976.001]
  • [Cites] Blood. 1989 Feb;73(2):601-5 [2917193.001]
  • [Cites] J Cell Biol. 1989 Aug;109(2):833-41 [2668305.001]
  • [Cites] Nature. 1990 Mar 22;344(6264):309-13 [2314472.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):380-9 [1692558.001]
  • [Cites] Br J Haematol. 1990 May;75(1):132-3 [2375912.001]
  • [Cites] Nature. 1991 Mar 21;350(6315):252-4 [1706482.001]
  • [Cites] Blood. 1991 May 1;77(9):2054-8 [2018842.001]
  • [Cites] EMBO J. 1991 Jun;10(6):1427-33 [1673924.001]
  • [Cites] Genes Dev. 1991 Aug;5(8):1387-94 [1714415.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):473-86 [8417345.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2776-86 [7682653.001]
  • [Cites] EMBO J. 1993 Jul;12(7):2723-33 [8334991.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4836-43 [8336720.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1493-500 [8288615.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):265-7 [7507641.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1184-97 [7926723.001]
  • [Cites] Mol Cell Biol. 1995 Feb;15(2):852-60 [7823951.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1955-9 [7829533.001]
  • [Cites] Nature. 1995 May 25;375(6529):316-8 [7753194.001]
  • [Cites] Nature. 1995 May 25;375(6529):318-22 [7753195.001]
  • [Cites] Dev Dyn. 1996 Jul;206(3):248-59 [8896981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12267-71 [8901569.001]
  • [Cites] Genes Dev. 1996 Nov 15;10(22):2894-902 [8918890.001]
  • [Cites] Cell. 1997 May 2;89(3):349-56 [9150134.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1291-9 [9242564.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2259-63 [9516123.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):112-24 [9887104.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1361-71 [15340042.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3707-14 [15537646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):11997-2002 [14514889.001]
  • [Cites] Stem Cells. 2003;21(6):632-7 [14595122.001]
  • [Cites] Methods Enzymol. 2003;365:39-59 [14696336.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4078-83 [14764531.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1495-509 [15198986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17065-70 [16286657.001]
  • [Cites] Acc Chem Res. 2006 Jan;39(1):45-52 [16411739.001]
  • [Cites] Gene. 2006 Jan 17;366(1):27-38 [16298089.001]
  • [Cites] Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):299-304 [10744425.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28549-54 [10878017.001]
  • [Cites] Cell. 1987 Dec 24;51(6):975-85 [3690667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13294-9 [11069298.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11323-34 [11145970.001]
  • [Cites] Cell. 2002 Apr 5;109(1):29-37 [11955444.001]
  • [Cites] EMBO Rep. 2002 Jul;3(7):610-5 [12101091.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):919-23 [12213587.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):623-6 [12426570.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1427-32 [12415262.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1453-65 [12504019.001]
  • [Cites] Nat Genet. 2003 Oct;35(2):190-4 [14517543.001]
  • (PMID = 17198872.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P60 HL28381; United States / NCI NIH HHS / CA / R24 CA088302; United States / NIDDK NIH HHS / DK / K08 DK002871; United States / NCI NIH HHS / CA / R24 CA88302; United States / NHLBI NIH HHS / HL / P60 HL028381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; 9004-22-2 / Globins
  • [Other-IDs] NLM/ NIHMS16214; NLM/ PMC1892846
  •  go-up   go-down


7. Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Rämer PC, Ferlazzo G, Münz C: Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood; 2010 Nov 18;116(20):4158-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate here that this model allows the development of all NK-cell subsets that are also found in human adult peripheral and cord blood, including NKp46(+)CD56(-) NK cells.
  • Similar to human cord blood, NK cells from these reconstituted mice require preactivation by interleukin-15 to reach the functional competence of human adult NK cells.
  • After preactivation, both CD16(+) and CD16(-) NK cells efficiently produce interferon-γ and degranulate in response to stimulation with NK cell-susceptible targets, including K562 erythroleukemia cells.

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Apr;5(4):405-11 [10202929.001]
  • [Cites] J Exp Med. 2009 Jun 8;206(6):1423-34 [19487422.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3886-93 [15319293.001]
  • [Cites] Blood. 2005 Jan 1;105(1):266-73 [15331446.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):727-34 [15634892.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4416-23 [15728129.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):709-13 [16079848.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] Annu Rev Immunol. 2006;24:287-320 [16551251.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):1033-43 [16606675.001]
  • [Cites] Immunity. 2006 Aug;25(2):331-42 [16901727.001]
  • [Cites] J Exp Med. 2000 Mar 6;191(5):771-80 [10704459.001]
  • [Cites] Immunity. 2000 Jul;13(1):143-53 [10933402.001]
  • [Cites] Annu Rev Immunol. 2001;19:197-223 [11244035.001]
  • [Cites] J Immunol Methods. 2001 Jun 1;252(1-2):83-92 [11334968.001]
  • [Cites] Blood. 2001 May 15;97(10):3146-51 [11342442.001]
  • [Cites] Eur J Immunol. 2001 Oct;31(10):3121-7 [11592089.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):327-33 [11828007.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):335-41 [11828008.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):343-51 [11828009.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1723-9 [11861289.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6178-86 [12414645.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):306-13 [12548561.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3052-7 [12480696.001]
  • [Cites] J Exp Med. 2003 Apr 21;197(8):977-84 [12695489.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):29-38 [12801296.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1333-9 [14734707.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1455-62 [14734722.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Exp Med. 1997 Jun 16;185(12):2079-88 [9182679.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):117-22 [9419217.001]
  • [Cites] Eur J Immunol. 2006 Sep;36(9):2394-400 [16917961.001]
  • [Cites] Nat Immunol. 2006 Nov;7(11):1217-24 [17013389.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4947-55 [17404276.001]
  • [Cites] Blood. 2007 May 1;109(9):3776-85 [17218381.001]
  • [Cites] Immunity. 2007 Apr;26(4):503-17 [17398124.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):89-94 [17579025.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3316-29 [17948125.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1313-23 [17982459.001]
  • [Cites] PLoS Pathog. 2008 Feb 8;4(2):e27 [18266470.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):7785-91 [18523242.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1231-9 [18519810.001]
  • [Cites] Immunol Rev. 2008 Aug;224:70-84 [18759921.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):6170-7 [18941207.001]
  • [Cites] J Exp Med. 2009 Jan 16;206(1):25-34 [19103877.001]
  • [Cites] J Exp Med. 2009 Feb 16;206(2):287-98 [19171762.001]
  • [Cites] J Clin Immunol. 2009 May;29(3):265-73 [19280325.001]
  • [Cites] Immunity. 2005 Mar;22(3):295-304 [15780987.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] J Exp Med. 2009 Jul 6;206(7):1495-503 [19528259.001]
  • [Cites] PLoS One. 2009;4(12):e8132 [19997637.001]
  • [Cites] PLoS One. 2009;4(12):e8379 [20027308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21783-8 [19966223.001]
  • [Cites] Nat Immunol. 2010 Apr;11(4):321-7 [20190757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11 [15536127.001]
  • (PMID = 20671122.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NCI NIH HHS / CA / CA108609-08; United States / NCI NIH HHS / CA / R01 CA101741; United States / NCI NIH HHS / CA / R01CA101741; United States / NCI NIH HHS / CA / R01CA108609; United States / NCI NIH HHS / CA / R01 CA108609-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD56; 0 / Interleukin-15; 0 / Natural Cytotoxicity Triggering Receptor 1; 0 / Receptors, Interleukin-2; 126465-35-8 / Perforin; 24939-03-5 / Poly I-C; 82115-62-6 / Interferon-gamma; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2993621
  •  go-up   go-down


8. Moore A, Merad Boudia M, Lehalle D, Massrieh W, Derjuga A, Blank V: Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor. Antioxid Redox Signal; 2006 Jan-Feb;8(1-2):68-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor.
  • The function of the NF-E2 transcription factor, a p45/small Maf heterodimer, was analyzed in the erythroleukemia cell lines MEL and CB3.
  • In contrast to MEL cells, CB3 cells are null for p45 and thus express only extremely low levels of adult globin transcripts upon induction by agents promoting erythroid differentiation.
  • We investigated the response of erythroleukemia cells to hemin treatment.
  • Stable expression of the large p45 NF-E2 subunit in CB3 cells restores hemin mediated beta-globin gene transcription, suggesting that the presence of a functional NF-E2 is required for strong induction of beta-globin mRNA levels by hemin in erythroleukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487039.001).
  • [ISSN] 1523-0864
  • [Journal-full-title] Antioxidants & redox signaling
  • [ISO-abbreviation] Antioxid. Redox Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / Protein Subunits; 42VZT0U6YR / Heme; 743LRP9S7N / Hemin; 9004-22-2 / Globins
  •  go-up   go-down


9. Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S: Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? Hematology; 2007 Oct;12(5):381-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?
  • The clinico-hematological profile of 40 cases of acute erythroleukemia (AEL) was evaluated.
  • [MeSH-minor] Adult. Age Factors. Aged. Cell Count. Erythroblasts. Erythroid Cells. Female. Granulocyte Precursor Cells. Humans. Incidence. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852448.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Emery DW, Gavriilidis G, Asano H, Stamatoyannopoulos G: The transcription factor KLF11 can induce gamma-globin gene expression in the setting of in vivo adult erythropoiesis. J Cell Biochem; 2007 Mar 1;100(4):1045-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor KLF11 can induce gamma-globin gene expression in the setting of in vivo adult erythropoiesis.
  • We report here that ectopic expression of KLF11 can also induce fetal gamma-globin gene expression in the setting of adult erythropoiesis both in vitro and in vivo.
  • Studies in an adult-stage murine erythroleukemia (MEL) cell line demonstrated that retrovirus vector-mediated transduction of KLF11 could increase both the amount of expression from a basally active, but not from a overtly silenced, recombinant gamma-globin transgene, as well as the frequency of cells expressing this transgene.
  • These studies provide the first evidence that ectopic expression of a transcription factor can induce gamma-globin gene expression in vivo during adult erythropoiesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131378.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; 9004-22-2 / Globins
  •  go-up   go-down


11. Robert-Moreno A, Espinosa L, Sanchez MJ, de la Pompa JL, Bigas A: The notch pathway positively regulates programmed cell death during erythroid differentiation. Leukemia; 2007 Jul;21(7):1496-503
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we show that the Notch/RBPjkappa signaling pathway induces erythroid apoptosis in different hematopoietic tissues, including yolk sac and bone marrow as well as in murine erythroleukemia cells.
  • We demonstrate that incubation with Jagged1-expressing cells has a proapoptotic effect in erythroid cells from adult bone marrow that is prevented by blocking Notch activity.
  • Finally, we show that the sole expression of the activated Notch1 protein is sufficient to induce apoptosis in hexametilene-bisacetamide-differentiating murine erythroleukemia cells.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17476283.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Notch1 protein, mouse; 0 / Receptor, Notch1; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins
  •  go-up   go-down


12. Lin IJ, Zhou Z, Crusselle-Davis VJ, Moghimi B, Gandhi K, Anantharaman A, Pantic D, Huang S, Jayandharan G, Zhong L, Srivastava A, Bungert J: Calpeptin increases the activity of upstream stimulatory factor and induces high level globin gene expression in erythroid cells. J Biol Chem; 2009 Jul 24;284(30):20130-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that the protein levels of upstream stimulatory factor (USF) increase during differentiation of murine erythroleukemia (MEL) cells.
  • Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF and strongly induced expression of the adult alpha- and beta-globin genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):369-78 [8995271.001]
  • [Cites] Nucleic Acids Res. 1993 Nov 11;21(22):5092-100 [8255762.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50350-7 [15385559.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):146-55 [15752978.001]
  • [Cites] Pigment Cell Res. 2005 Oct;18(5):337-48 [16162174.001]
  • [Cites] Cell Biochem Biophys. 2006;45(2):147-56 [16757815.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6832-43 [16943425.001]
  • [Cites] Science. 2006 Oct 6;314(5796):122-5 [17023658.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):1037-46 [17272500.001]
  • [Cites] FEBS J. 2007 Dec;274(23):6065-73 [17970752.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1920-3 [18063756.001]
  • [Cites] Curr Opin Immunol. 2008 Jun;20(3):250-8 [18515054.001]
  • [Cites] Exp Hematol. 2008 Sep;36(9):1057-72 [18718415.001]
  • [Cites] Biol Reprod. 2009 Jan;80(1):24-33 [18768914.001]
  • [Cites] Nature. 2009 Feb 26;457(7233):1103-8 [19242469.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1140-8 [10648599.001]
  • [Cites] J Exp Med. 2000 Nov 20;192(10):1479-90 [11085749.001]
  • [Cites] Biol Chem. 2002 May;383(5):757-64 [12108540.001]
  • [Cites] Cell. 2002 Nov 15;111(4):529-41 [12437926.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):1292-301 [12582249.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):731-801 [12843408.001]
  • [Cites] Cell. 1976 Oct;9(2):221-9 [975244.001]
  • [Cites] J Cell Biol. 1981 Aug;90(2):542-4 [6793600.001]
  • [Cites] J Biol Chem. 1985 Apr 25;260(8):4884-9 [3857230.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1362-70 [2001459.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):315-25 [8381210.001]
  • [Cites] Biochim Biophys Acta. 1993 Aug 18;1178(2):207-14 [8347679.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18824-34 [8360172.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):355-9 [8377828.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):1-10 [15541720.001]
  • (PMID = 19491096.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356; United States / NIDDK NIH HHS / DK / DK052356-15A1; United States / NHLBI NIH HHS / HL / R01 HL090589; United States / NIDDK NIH HHS / DK / DK052356; United States / NIDDK NIH HHS / DK / R01 DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356-15A1; United States / NHLBI NIH HHS / HL / HL090589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Upstream Stimulatory Factors; 117591-20-5 / calpeptin; 9004-22-2 / Globins; EC 2.7.7.- / RNA Polymerase II; EC 3.4.22.- / Calpain; EC 3.4.22.- / m-calpain
  • [Other-IDs] NLM/ PMC2740439
  •  go-up   go-down


13. Shyu YC, Wen SC, Lee TL, Chen X, Hsu CT, Chen H, Chen RL, Hwang JL, Shen CK: Chromatin-binding in vivo of the erythroid kruppel-like factor, EKLF, in the murine globin loci. Cell Res; 2006 Apr;16(4):347-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EKLF was found to bind in vivo at both the mouse beta-major-globin promoter and the HS2 site of beta-LCR in the mouse erythroleukemia cells (MEL) in a DMSO-inducible manner.
  • Interestingly, binding of EKLF in vivo was also detected in the mouse alpha-like globin locus, at the adult alpha globin promoter and its far upstream regulatory element alpha-MRE (HS26).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617330.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / Nfe2 protein, mouse; 0 / erythroid Kruppel-like factor; 9004-22-2 / Globins
  •  go-up   go-down


14. Blau CA, Barbas CF 3rd, Bomhoff AL, Neades R, Yan J, Navas PA, Peterson KR: {gamma}-Globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human {beta}-globin locus yeast artificial chromosome ({beta}-YAC) transgenic mice. J Biol Chem; 2005 Nov 4;280(44):36642-7
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human K562 cells co-express epsilon- and gamma-globin but not beta-globin; transgenic mouse erythroleukemia 585 cells express predominantly human beta-globin but also gamma-globin; and transgenic murine GM979 cells co-express human gamma-and beta-globin.
  • We rationalized that cells established from the adult bone marrow of these mice might express exclusively beta-globin and therefore could be employed to select or screen inducers of gamma-globin expression.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131492.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK52997; United States / NIDDK NIH HHS / DK / DK53510; United States / NIDDK NIH HHS / DK / DK61803; United States / NIDDK NIH HHS / DK / DK61804; United States / NHLBI NIH HHS / HL / HL53750; United States / NHLBI NIH HHS / HL / HL67336
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-22-2 / Globins; 9034-63-3 / Fetal Hemoglobin; M801H13NRU / Azacitidine
  •  go-up   go-down


15. Quadrini KJ, Bieker JJ: EKLF/KLF1 is ubiquitinated in vivo and its stability is regulated by activation domain sequences through the 26S proteasome. FEBS Lett; 2006 Apr 17;580(9):2285-93
Hazardous Substances Data Bank. L-Lysine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erythroid Krüppel-like factor (EKLF/KLF1) is an erythroid specific, C(2)H(2) zinc finger transcription factor that is essential for the proper chromatin structure and expression of the adult beta-globin gene.
  • Herein, we determine that 26S proteasome inhibitors lead to an accumulation of EKLF protein in murine erythroleukemia (MEL) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579989.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK46865; United States / NIGMS NIH HHS / GM / T32 GM08553
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromatin; 0 / Kruppel-Like Transcription Factors; 0 / Ubiquitin; 0 / erythroid Kruppel-like factor; 9004-22-2 / Globins; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.4.99.- / ATP dependent 26S protease; K3Z4F929H6 / Lysine
  •  go-up   go-down


16. Zhou Z, Li X, Deng C, Ney PA, Huang S, Bungert J: USF and NF-E2 cooperate to regulate the recruitment and activity of RNA polymerase II in the beta-globin gene locus. J Biol Chem; 2010 May 21;285(21):15894-905

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we demonstrate that although USF is required for the efficient association of RNA polymerase II (Pol II) with immobilized LCR templates, USF and NF-E2 together regulate the association of Pol II with the adult beta-globin gene promoter.
  • Recruitment of Pol II to the LCR occurs in undifferentiated murine erythroleukemia cells, but phosphorylation of LCR-associated Pol II at serine 5 of the C-terminal domain is mediated by erythroid differentiation and requires the activity of NF-E2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2485-90 [15489291.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(19):6384-8 [3879975.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cell. 1987 Dec 24;51(6):975-85 [3690667.001]
  • [Cites] Nucleic Acids Res. 1987 Dec 23;15(24):10159-77 [3480506.001]
  • [Cites] Genes Dev. 1990 Jun;4(6):993-1006 [2116990.001]
  • [Cites] Nat Genet. 2003 Oct;35(2):190-4 [14517543.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3989-97 [12920025.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4223-8 [12920035.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jan;11(1):73-80 [14718926.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1461-6 [14747657.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2437-68 [15489290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18303-8 [19822740.001]
  • [Cites] Nature. 1994 Feb 10;367(6463):568-72 [8107826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8398-402 [8078893.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):106-16 [7828582.001]
  • [Cites] Cell. 1995 Jun 2;81(5):695-704 [7774011.001]
  • [Cites] Genes Dev. 1990 Oct;4(10):1730-40 [2249772.001]
  • [Cites] Cell. 1991 Sep 6;66(5):981-93 [1889091.001]
  • [Cites] J Mol Biol. 1992 Feb 20;223(4):885-98 [1538403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11219-23 [1454801.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18824-34 [8360172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11488-92 [8265578.001]
  • [Cites] Eur J Biochem. 2002 Mar;269(6):1589-99 [11895428.001]
  • [Cites] J Leukoc Biol. 2002 Apr;71(4):545-56 [11927640.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e44 [12000849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11760-5 [12193659.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):448-53 [12540921.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):1292-301 [12582249.001]
  • [Cites] Genes Dev. 2003 Apr 15;17(8):1009-18 [12672691.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6484-93 [12944475.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4640-7 [7623856.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6055-64 [8887635.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):369-78 [8995271.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2509-15 [9171106.001]
  • [Cites] Nucleic Acids Res. 1997 Aug 1;25(15):2953-59 [9224592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10051-6 [9294161.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5358-65 [9478996.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Apr;30(4):429-32 [9675875.001]
  • [Cites] Cell. 1998 Oct 2;95(1):93-104 [9778250.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2465-77 [10521391.001]
  • [Cites] Mol Cell. 2004 Nov 5;16(3):453-63 [15525517.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50350-7 [15385559.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):453-62 [15694345.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):259-71 [15730849.001]
  • [Cites] Nat Rev Genet. 2005 Sep;6(9):669-77 [16094312.001]
  • [Cites] FEBS J. 2006 Feb;273(4):746-55 [16441661.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1447-57 [16705039.001]
  • [Cites] EMBO J. 2006 Aug 9;25(15):3586-95 [16858401.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6832-43 [16943425.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16544-52 [17428799.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):307-14 [17534154.001]
  • [Cites] PLoS One. 2007;2(7):e630 [17637845.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):573-84 [17707229.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6777-94 [17934485.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):7991-8002 [17846119.001]
  • [Cites] FEBS J. 2007 Dec;274(23):6065-73 [17970752.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] J Cell Biochem. 2008 Sep 1;105(1):9-16 [18500726.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1547-54 [19008453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4213-8 [19251649.001]
  • [Cites] Nat Rev Genet. 2009 Jul;10(7):457-66 [19506577.001]
  • [Cites] J Biol Chem. 2009 Jul 24;284(30):20130-5 [19491096.001]
  • [Cites] Mol Cell Biol. 2009 Nov;29(21):5900-10 [19704006.001]
  • [Cites] Blood. 2000 Jul 1;96(1):334-9 [10891470.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10715-21 [11154691.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2629-40 [11283243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10226-31 [11517325.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):465-71 [11545748.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34355-8 [11443140.001]
  • (PMID = 20236933.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK052356-10; United States / NHLBI NIH HHS / HL / HL091929; United States / NHLBI NIH HHS / HL / R01 HL091929; United States / NIDDK NIH HHS / DK / R01 DK052356; United States / NIDDK NIH HHS / DK / DK052356-15A1; United States / NIDDK NIH HHS / DK / DK052356; United States / NIDDK NIH HHS / DK / R01 DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356-15A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / NFE2 protein, human; 0 / Nfe2 protein, mouse; 0 / beta-Globins; EC 2.7.7.- / RNA Polymerase II
  • [Other-IDs] NLM/ PMC2871457
  •  go-up   go-down


17. Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, Talmant P, Bastard C, Charrin C, Baranger L, Hélias C, Cornillet-Lefebvre P, Mugneret F, Cabrol C, Pagès MP, Fert-Ferret D, Nguyen-Khac F, Quilichini B, Barin C, Berger R, Groupe Francophone de Cytogénétique Hématologique (GFCH): Cytogenetic study of 75 erythroleukemias. Cancer Genet Cytogenet; 2005 Dec;163(2):113-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal abnormalities of erythroleukemia (EL) are often described as complex and unspecific.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosomes, Human. Humans. Middle Aged. Ploidies. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337853.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Glasser L, Meloni-Ehrig A, Greaves W, Demel KC, Butera J: Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. Transfusion; 2009 Mar;49(3):555-62
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The recipient-sister's original diagnosis was erythroleukemia.
  • [MeSH-minor] Adult. Chromosomes, Human / genetics. Female. Humans. Immunophenotyping. Karyotyping. Transplantation, Homologous / immunology


19. Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP: Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol; 2008 Nov;21(11):1394-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the FAB (French-American-British) and WHO (World Heath Organization) classifications, the blasts in erythroleukemia (M6a) are enumerated from the marrow nonerythroid rather than the total-nucleated cells.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839018.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Wen J, Huang S, Rogers H, Dickinson LA, Kohwi-Shigematsu T, Noguchi CT: SATB1 family protein expressed during early erythroid differentiation modifies globin gene expression. Blood; 2005 Apr 15;105(8):3330-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show SATB1 family protein induction during early human adult erythroid progenitor cell differentiation concomitant with epsilon-globin expression.
  • Erythroid differentiation of human erythroleukemia K562 cells by hemin simultaneously increases gamma-globin and down-regulates SATB1 family protein and epsilon-globin gene expression.

  • Institute for Transcriptional Informatics. gene/protein/disease-specific - Institute for Transcriptional Informatics (registration required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15618465.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Matrix Attachment Region Binding Proteins; 0 / Nuclear Proteins; 0 / SATB1 protein, human; 0 / Trans-Activators; 743LRP9S7N / Hemin; 9004-22-2 / Globins
  •  go-up   go-down


21. Ochsenreither S, Reinwald M, Thiel E, Burmeister T: Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine. Mol Diagn Ther; 2010 Jun 1;14(3):185-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A human erythroleukemia cell line (HEL) was used as a positive control in a 3-fold lower concentration than the negative control because of the gene amplification of the mutated JAK2 kinase in this cell line.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Substitution / genetics. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Health Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560681.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


22. Das KC, Das M, Mohanty D, Jadaon MM, Gupta A, Marouf R, Easow SK: Megaloblastosis: from morphos to molecules. Med Princ Pract; 2005;14 Suppl 1:2-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, megaloblastic changes in the bone marrow of human patients with myelodysplastic syndrome and erythroleukemia were not associated with this DNA synthetic abnormality.
  • [MeSH-minor] Adolescent. Adult. Animals. Case-Control Studies. Child. Cytogenetic Analysis. DNA / biosynthesis. Female. Folic Acid Deficiency / physiopathology. Genetic Markers. Histone Code. Humans. Macaca mulatta. Male. Microscopy, Electron, Transmission. Rats. Rats, Wistar. Suppression, Genetic. Vitamin B 12 Deficiency / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 16103708.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Histones; 9007-49-2 / DNA
  •  go-up   go-down


23. de Vooght KM, van Solinge WW, van Wesel AC, Kersting S, van Wijk R: First mutation in the red blood cell-specific promoter of hexokinase combined with a novel missense mutation causes hexokinase deficiency and mild chronic hemolysis. Haematologica; 2009 Sep;94(9):1203-10
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: Functional studies were performed using transient transfection of HK promoter constructs in human K562 erythroleukemia cells.
  • [MeSH-minor] Adult. Amino Acid Substitution. Chronic Disease. Exons / genetics. Humans. K562 Cells. Male. RNA Splicing / genetics. Response Elements / genetics. Transcription, Genetic / genetics


24. Zeng R, Chen Y: [Biological characteristics and therapeutic effect of acute erytho-leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun;15(3):466-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to investigate the biological characteristics and the therapeutic effect in patients with acute erythroleukemia (AML-M(6)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605846.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Membrane Glycoproteins
  •  go-up   go-down






Advertisement